SE9102074D0 - Tomour antigen specific antibody - Google Patents

Tomour antigen specific antibody

Info

Publication number
SE9102074D0
SE9102074D0 SE9102074A SE9102074A SE9102074D0 SE 9102074 D0 SE9102074 D0 SE 9102074D0 SE 9102074 A SE9102074 A SE 9102074A SE 9102074 A SE9102074 A SE 9102074A SE 9102074 D0 SE9102074 D0 SE 9102074D0
Authority
SE
Sweden
Prior art keywords
tomour
antibody
specific antibody
antigen specific
antigen
Prior art date
Application number
SE9102074A
Other languages
English (en)
Swedish (sv)
Inventor
L G Lindholm
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9102074A priority Critical patent/SE9102074D0/xx
Publication of SE9102074D0 publication Critical patent/SE9102074D0/xx
Priority to PCT/SE1992/000495 priority patent/WO1993001302A1/en
Priority to IL10239092A priority patent/IL102390A/en
Priority to KR1019930704117A priority patent/KR100246681B1/ko
Priority to NZ243435A priority patent/NZ243435A/en
Priority to PCT/SE1992/000502 priority patent/WO1993001303A1/en
Priority to AT92850166T priority patent/ATE171193T1/de
Priority to ES92850166T priority patent/ES2124250T3/es
Priority to AU19425/92A priority patent/AU658198B2/en
Priority to EP92850166A priority patent/EP0521842B1/en
Priority to DE69226990T priority patent/DE69226990T2/de
Priority to HU9400011A priority patent/HU218084B/hu
Priority to JP17584892A priority patent/JP3194020B2/ja
Priority to IE922188A priority patent/IE80841B1/en
Priority to DK92850166T priority patent/DK0521842T3/da
Priority to CA002073124A priority patent/CA2073124C/en
Priority to AU22920/92A priority patent/AU2292092A/en
Priority to NO19934777A priority patent/NO315472B1/no
Priority to FI935970A priority patent/FI109207B/fi
Priority to EE9400328A priority patent/EE03031B1/xx
Priority to US08/438,123 priority patent/US5552293A/en
Priority to HU95P/P00289P priority patent/HU211512A9/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE9102074A 1991-07-03 1991-07-03 Tomour antigen specific antibody SE9102074D0 (sv)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody
PCT/SE1992/000495 WO1993001302A1 (en) 1991-07-03 1992-07-02 Tumor, carbohydrate antigen specific monoclonal antibody and cell line
IL10239092A IL102390A (en) 1991-07-03 1992-07-02 Antibody specific for malignant tumors, its use and cell lines that produce this antibody
AU22920/92A AU2292092A (en) 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line
DE69226990T DE69226990T2 (de) 1991-07-03 1992-07-03 Tumorantigen-spezifischer Antikörper
JP17584892A JP3194020B2 (ja) 1991-07-03 1992-07-03 腫瘍抗原特異的抗体、それを含む医薬組成物およびその抗体を産生する細胞系
PCT/SE1992/000502 WO1993001303A1 (en) 1991-07-03 1992-07-03 Tumor, carbohydrate antigen specific monoclonal antibody and cell line
AT92850166T ATE171193T1 (de) 1991-07-03 1992-07-03 Tumorantigen-spezifischer antikörper
ES92850166T ES2124250T3 (es) 1991-07-03 1992-07-03 Anticuerpo especifico para un antigeno tumoral.
AU19425/92A AU658198B2 (en) 1991-07-03 1992-07-03 Tumour antigen specific antibody, its use and cell in line producing the antibody
EP92850166A EP0521842B1 (en) 1991-07-03 1992-07-03 Tumor antigen specific antibody
KR1019930704117A KR100246681B1 (ko) 1991-07-03 1992-07-03 종양, 탄수화물 항원에 특이한 모노클로날 항체 및 세포계
HU9400011A HU218084B (hu) 1991-07-03 1992-07-03 Daganatokra specifikus monoklonális antitest és sejtvonal, valamint ezeket tartalmazó gyógyászati készítmények
NZ243435A NZ243435A (en) 1991-07-03 1992-07-03 Monoclonal antibody specific for a tumour antigen, its use and the cell line responsible for its production
IE922188A IE80841B1 (en) 1991-07-03 1992-07-03 Tumor antigen specific antibody
DK92850166T DK0521842T3 (da) 1991-07-03 1992-07-03 Tumorantigenspecifikt antistof
CA002073124A CA2073124C (en) 1991-07-03 1992-07-03 Tumor antigen specific antibody
NO19934777A NO315472B1 (no) 1991-07-03 1993-12-22 Tumor, karbohydratantigen spesifikt monoklonalt antistoff og cellelinje, farmasöytisk sammensetning og fremgangsmåte for invitro diagnostikk
FI935970A FI109207B (fi) 1991-07-03 1993-12-31 Tuumori/hiilihydraattiantigeenispesifinen monoklonaalinen vasta-aine ja solulinja
EE9400328A EE03031B1 (et) 1991-07-03 1994-11-16 Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid
US08/438,123 US5552293A (en) 1991-07-03 1995-05-08 Tumor antigen specific antibody
HU95P/P00289P HU211512A9 (en) 1991-07-03 1995-06-20 Tumor antigen specific antibody and cell line, and pharmaceutical composition comprising them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Publications (1)

Publication Number Publication Date
SE9102074D0 true SE9102074D0 (sv) 1991-07-03

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Country Status (19)

Country Link
US (1) US5552293A (xx)
EP (1) EP0521842B1 (xx)
JP (1) JP3194020B2 (xx)
KR (1) KR100246681B1 (xx)
AT (1) ATE171193T1 (xx)
AU (2) AU2292092A (xx)
CA (1) CA2073124C (xx)
DE (1) DE69226990T2 (xx)
DK (1) DK0521842T3 (xx)
EE (1) EE03031B1 (xx)
ES (1) ES2124250T3 (xx)
FI (1) FI109207B (xx)
HU (2) HU218084B (xx)
IE (1) IE80841B1 (xx)
IL (1) IL102390A (xx)
NO (1) NO315472B1 (xx)
NZ (1) NZ243435A (xx)
SE (1) SE9102074D0 (xx)
WO (2) WO1993001302A1 (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1411962B1 (en) * 2001-03-15 2011-01-19 Neogenix Oncology, Inc. Monoclonal antibody therapy for pancreas cancer
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
US20060246060A1 (en) * 2002-07-02 2006-11-02 Nesta Douglas P Novel stable formulation
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
DK1651162T3 (en) 2003-05-20 2016-02-01 Immunogen Inc IMPROVED CYTOTOXIC AGENTS WITH NEW MAYTANSINOIDS
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US20060182750A1 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing stable drug conjugates
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
NZ595386A (en) * 2005-08-11 2013-08-30 Arpi Matossian Rogers Peptides for treatment and diagnosis of autoimmune disease
EP1928503B1 (en) 2005-08-24 2012-10-03 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
KR20160039295A (ko) 2008-08-05 2016-04-08 도레이 카부시키가이샤 암의 검출 방법
PL2437790T3 (pl) 2009-06-03 2019-09-30 Immunogen, Inc. Sposoby sprzęgania
KR20220123130A (ko) 2011-03-29 2022-09-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
EP3220959A1 (en) 2014-11-19 2017-09-27 ImmunoGen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
KR20180100412A (ko) 2016-01-10 2018-09-10 네오티엑스 테라퓨틱스 엘티디. 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
RU2018130108A (ru) 2016-02-05 2020-03-06 Иммуноджен, Инк. Эффективный способ получения конъюгатов связывающийся с клеткой агент цитотоксический агент
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
AU2020275142A1 (en) 2019-05-15 2021-12-16 Neotx Therapeutics Ltd. Cancer treatment
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
JPH06500077A (ja) * 1990-07-20 1994-01-06 カビ・フアーマシア・アクチエボラーグ 接合体物質、試薬および新規なポリエーテル
ES2094231T3 (es) * 1990-07-20 1997-01-16 Pharmacia & Upjohn Ab Conjugados de anticuerpos superantigenos especificos de una diana y su preparacion.

Also Published As

Publication number Publication date
ES2124250T3 (es) 1999-02-01
WO1993001303A1 (en) 1993-01-21
CA2073124A1 (en) 1993-01-04
NO934777L (no) 1994-02-11
KR100246681B1 (ko) 2000-04-01
US5552293A (en) 1996-09-03
EP0521842A3 (xx) 1994-01-26
HU9400011D0 (en) 1994-05-30
NO934777D0 (no) 1993-12-22
ATE171193T1 (de) 1998-10-15
CA2073124C (en) 2007-06-19
HU211512A9 (en) 1995-11-28
IE922188A1 (en) 1993-01-13
DK0521842T3 (da) 1999-06-14
EE03031B1 (et) 1997-08-15
JPH05276987A (ja) 1993-10-26
IL102390A (en) 1996-01-19
EP0521842B1 (en) 1998-09-16
AU658198B2 (en) 1995-04-06
JP3194020B2 (ja) 2001-07-30
DE69226990T2 (de) 1999-03-25
FI935970A (fi) 1993-12-31
HU218084B (hu) 2000-05-28
FI935970A0 (fi) 1993-12-31
DE69226990D1 (de) 1998-10-22
HUT71193A (en) 1995-11-28
NO315472B1 (no) 2003-09-08
WO1993001302A1 (en) 1993-01-21
NZ243435A (en) 1994-10-26
IE80841B1 (en) 1999-03-24
IL102390A0 (en) 1993-01-14
EP0521842A2 (en) 1993-01-07
AU1942592A (en) 1993-01-07
FI109207B (fi) 2002-06-14
AU2292092A (en) 1993-02-11

Similar Documents

Publication Publication Date Title
SE9102074D0 (sv) Tomour antigen specific antibody
FI101937B1 (fi) Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
DE69127487D1 (de) Verfahren zum Nachweis der Alzheimer-Krankheit
DE3684211D1 (xx)
ATE110109T1 (de) Monoklonaler antikörper gegen kern-hcg-beta, seine herstellung und verwendung.
DE3688204D1 (de) Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens.
ATE116004T1 (de) Antikörper gegen menschliches sperma, ihre herstellung und anwendung.
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
DE69124317D1 (de) Monoklonale Antikörper gegen Leptosphaeria
IL97622A (en) Monoclonal antibodies that inhibit growth of kaposi's sarcoma
ATE136937T1 (de) Antikörper gegen hamsterimmunglobulinen
ATE148162T1 (de) Monoklonale antikörper gegen mycosphaerella-arten
IT8020164A0 (it) Procedimento per produrre colture sporifere di un ceppo di clavicepspurpurea virulento sulla segale e producente l'ergocristina.
DK182188A (da) Humant tumorassocieret antigen